Circulating levels of heart-type fatty acid-binding protein and its relation to thallium-201 perfusion defects in patients with hypertrophic cardiomyopathy

American Journal of Cardiology

Volumn 95, Issue 11, 2005, Pages 1334-1337

  Morioka, Norikatsu ^a   Shigematsu, Yuji ^b   Hamada, Mareomi ^b   Higaki, Jitsuo ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; MYOGLOBIN; THALLIUM 201;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DETERIORATION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HEART MUSCLE INJURY; HEART PERFUSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; ECHOCARDIOGRAPHY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOGLOBIN; RADIOPHARMACEUTICALS; THALLIUM RADIOISOTOPES;

EID: 19344373340     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.01.078     Document Type: Article

References (27)

1. F.G. Schaap, G.J. van der Vusse, J.F. Glatz Fatty acid-binding proteins in the heart Mol Cell Biochem 180 1998 43 51
2. K. Setsuta, Y. Seino, T. Ogawa, M. Arao, Y. Miyatake, T. Takano Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure Am J Med 113 2002 717 722
3. F.A. Van Nieuwenhoven, A.H. Kleine, W.H. Wodzig, W.T. Hermens, H.A. Kragten, J.G. Maessen, C.D. Punt, M.P. Van Dieijen, G.J. Van der Vusse, J.F. Glatz Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein Circulation 92 1995 2848 2854
4. P. Richardson, W. McKenna, M. Bristow, B. Maisch, B. Mautner, J. O'Connell, E. Olsen, G. Thiene, J. Goodwin, I. Gyarfas, I. Martin, P. Nordet Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies Circulation 93 1996 841 842
5. M. Hamada, Y. Shigematsu, H. Kawakami, N. Minamino, K. Kangawa, H. Matsuo, K. Hiwada Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-I, natriuretic peptides and noradrenaline Clin Sci 94 1998 21 28
6. M. Abe, M. Hamada, H. Matsuoka, Y. Shigematsu, T. Sumimoto, K. Hiwada Myocardial scintigraphic characteristics in patients with primary aldosteronism Hypertension 23 suppl 1 1994 164 167
7. L.T. Chang A method for attenuation correction in radionuclide computed tomography IEEE Trans Nucl Sci 25 1978 638 643
8. E.V. Garcia, K. Van Train, J. Maddahi, F. Prigent, J. Friedman, J. Areeda, A. Waxman, D.S. Berman Quantification of rotational thallium-201 myocardial tomography J Nucl Med 26 1985 17 26
9. D.J. Sahn, A. DeMaria, J. Kisslo, A. Weyman Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements Circulation 58 1978 1072 1083
10. P. Spirito, B.J. Maron, R.O. Bonow, S.E. Epstein Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy Am J Cardiol 60 1987 123 129
11. B.J. Maron, P. Spirito Implications of left ventricular remodeling in hypertrophic cardiomyopathy Am J Cardiol 81 1998 1339 1344
12. B.J. Maron, I. Olivotto, P. Spirito, S.A. Casey, P. Bellone, T.E. Gohman, K.J. Graham, D.A. Burton, F. Cecchi Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population Circulation 102 2000 858 864
13. S. Nagata, Y. Park, T. Minamikawa, C. Yutani, T. Kamiya, T. Nishimura, T. Kozuka, H. Sakakibara, Y. Nimura Thallium perfusion and cardiac enzyme abnormalities in patients with familial hypertrophic cardiomyopathy Am Heart J 109 1985 1317 1322
14. M. Hamada, T. Ohtani, M. Sekiya, Y. Fujiwara, T. Sumimoto, K. Hiwada, S. Morita, H. Tsukada Serum creatine kinase MM isoforms in hypertrophic cardiomyopathy Clin Sci 81 1991 723 726
15. K. Hina, S. Kusachi, K. Iwasaki, A. Takaishi, K. Yamamoto, Y. Tominaga, T. Kita, T. Tsuji Use of serum creatine kinase MM isoforms for predicting the progression of left ventricular dilation in patients with hypertrophic cardiomyopathy Jpn Circ J 61 1997 315 322
16. P.T. O'Gara, R.O. Bonow, B.J. Maron, B.A. Damske, A. Van Lingen, S.L. Bacharach, S.M. Larson, S.E. Epstein Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography Circulation 76 1987 1214 1223
17. T.W. von Dohlen, L.M. Prisant, M.J. Frank Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy Am J Cardiol 64 1989 498 503
18. A.P. Nielsen, K.G. Morris, R. Murdock, F.P. Bruno, F.R. Cobb Linear relationship between the distribution of thallium-201 and blood flow in ischemic and nonischemic myocardium during exercise Circulation 61 1980 797 801
19. D. McCall, L.J. Zimmer, A.M. Katz Kinetics of thallium exchange in cultured rat myocardial cells Circ Res 56 1985 370 376
20. R. Krams, M.J. Kofflard, D.J. Duncker, C. Von Birgelen, S. Carlier, M. Kliffen, F.J. ten Cate, P.W. Serruys Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation Circulation 97 1998 230 233
21. B. Schwartzkopff, M. Mundhenke, B.E. Strauer Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia J Am Coll Cardiol 31 1998 1089 1096
22. B.J. Maron, J.K. Wolfson, S.E. Epstein, W.C. Roberts Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy J Am Coll Cardiol 8 1986 545 557
23. R.O. Cannon III, D.R. Rosing, B.J. Maron, M.B. Leon, R.O. Bonow, R.M. Watson, S.E. Epstein Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures Circulation 71 1985 234 243
24. T. Ino, K. Nishimoto, M. Okubo, K. Akimoto, K. Yabuta, S. Kawai, R. Okada, N. Sueyoshi Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy Am J Cardiol 79 1997 1137 1141
25. H. Saeki, M. Hamada, K. Hiwada Circulating levels of insulin-like growth factor-1 and its binding proteins in patients with hypertrophic cardiomyopathy Circ J 66 2002 639 644
26. M. Hamada, Y. Shigematsu, S. Ikeda, Y. Hara, H. Okayama, K. Kodama, T. Ochi, K. Hiwada Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy Circulation 96 1997 1520 1524
27. B.J. Maron, V.N. Tholakanahalli, A.G. Zenovich, S.A. Casey, D. Duprez, D.M. Aeppli, J.N. Cohn Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy Circulation 109 2004 984 989